Oscar Fairs from Benfleet, Essex, was diagnosed with a rare 7cm ependymoma brain tumour in August 2023 and underwent seven surgeries, one round of chemotherapy and one round of radiotherapy to be told palliative care was the only option. A GoFundMe page was set up to help the family raise £100,000 towards a treatment trial in France. It is with deep and profound sadness that West Ham United confirm the tragic passing of our U15s Academy goalkeeper Oscar Fairs, following his brave battle with cancer. Rest in peace, brave Oscar. — West Ham United (@WestHam) December 13, 2024 West Ham footballers donated £27,000, chairman David Sullivan donated £10,000 and Arsenal footballer and former West Ham star Declan Rice gave £5,000, according to Ms Fairs. On Friday, West Ham announced that the 15-year-old had died. Sporting director Mark Noble said: “Oscar was adored by everyone at the Academy – not only was he a great goalkeeper, he was a true Hammer and a fantastic young person, who will be deeply missed by everyone who had the pleasure to know him. “I have wonderful memories of Oscar playing in my garden – (my son) Lenny and his teammates all loved him. “He was a friendly, happy, well-mannered and polite young man, who had such a bright future ahead of him, and it is just so unimaginably devastating that he has been taken from his family and friends at this age. “The thoughts and sincere condolences of everyone at the Club are with Oscar’s parents, Natalie and Russell, and his brother Harry, and we kindly ask that the family’s privacy is respected at this extremely difficult time.” All scheduled Academy fixtures over the weekend have been postponed as a mark of respect.Tighter wheat means higher prices

During Donald Trump’s first term, U.S. tariffs on China increased from 3% in 2016 to 19% by the end of 2020. As a result, China’s share of the U.S. trade deficit dropped from 47% to 26%. However, it’s worth noting that America’s trade imbalance continued to rise, as production shifted to low-tariff countries such as Vietnam, Canada, and Mexico. When Biden came into office, the expectation was that he might roll back the China tariffs. He didn’t. In fact, the Biden administration ramped up the trade war quite a bit. In 2022, strict restrictions on U.S. technology exports to China were implemented. The primary target was advanced chips such as NVIDIA GPUs, which are critical for AI and other emerging technologies. The equipment used to manufacture such tech was also heavily restricted. This mostly affected ASML, a Dutch company responsible for making the machines that manufacture advanced semiconductors. Today, China is completely cut off from the most advanced chips and the ability to use foreign tech to build them. These restrictions have hampered China’s ability to build advanced AI data centers, and their problem will only get worse until the country can build up its own semiconductor industry to be competitive with the U.S. and Taiwan. Or until they can strike a deal to reopen access to the technology. Xi Strikes Back, Drone Wars Begin A few weeks ago China fired a salvo aimed squarely at key U.S. industries. The country heavily restricted exports to America of critical minerals and rare earth elements. Included in the list were antimony, graphite, gallium, and many more. These minerals are critical for manufacturing lithium batteries, weapons, semiconductors, fiber optic cable, and other high-tech necessities. And China dominates their production currently. This will become a significant issue as existing stocks start to run low. Additionally, in early 2025, China will begin severe export restrictions on drones and parts used to manufacture them. Skydio, the largest American drone manufacturer, has already begun a policy of rationing batteries to one per drone. The company’s CEO explained the situation in a blog post : “As a result of the sanctions, our battery supply will be reduced for the next few months which will impact our customers. We have always manufactured our drones in the U.S., and over the last few years, we invested massively in bringing up supply for drone components outside of China. Batteries are one of the few components we have not yet moved out of China. We have a substantial stock of batteries on hand, and our team was already developing alternative suppliers. But right now we don’t expect new sources to come online until the spring of next year.” Skydio supplies both the American and Ukrainian militaries. So this is clearly a strategic move by China. It will take time to build alternative supply lines in this area, and drones have become absolutely critical to modern warfare. And isn’t it interesting that all of this is happening while there’s an unprecedented number of mysterious drone sightings across the country? My guess is the U.S. government is demonstrating to adversaries that we have advanced drone programs too, and won’t be intimidated. But we’ll continue to monitor that story. Just Getting Started The trade war is getting hot, and Trump isn’t even in office yet. There are massive imbalances in global trade which must be dealt with. America has lost its manufacturing edge, and it’s probably not coming back without aggressive trade and monetary policies. If we simply let the status quo continue, it’s likely that China would continue to dominate global production. The CCP is subsidizing industries, and suppressing its currency, and as a result, has gained a significant advantage in manufacturing expertise. Trump’s task is to build back America’s industrial base by encouraging domestic production. In trade, he will need to carefully balance the carrot with the stick. We are too interdependent with China to simply cut things off completely. Yet the current situation is also unsustainable. Government should encourage U.S. production of critical items such as semiconductors and batteries while maintaining enough of a relationship with China that trade lanes stay open in the meantime. It comes down to putting the right incentives in place and spending wisely. Ultimately, rebuilding U.S. industry may also require a weaker dollar. With the dollar so expensive compared to other fiat currencies today, it’s difficult for our exporters to compete with China and others on price. It will be interesting to see what President Trump does in this area. President Trump will need to utilize every bit of his deal-making chops in this upcoming term. The future of the American economy depends greatly on the agreements which will be struck over the next 4 years.Facebook Twitter WhatsApp SMS Email Print Copy article link Save Two fourth-quarter touchdowns powered top-seeded Archbishop Shaw to 28-25 victory over E.D. White in the Division II select title game that opened Friday’s action at the LHSAA Prep Classic. Michigan signee Jasper Parker ran for 174 yards on 19 carries and scored the go-ahead touchdown on a 62-yard run with 8:59 left in the game played at the Caesars Superdome. Shaw (12-2) won its first LHSAA title since 1987. Quarterback Mason Wilson added 88 yards on 16 carries and also completed 10 of 19 passes for 111 yards for the Eagles of coach Hank Tierney, who also coached to its 1987 title. E.D. White (11-3) was led by quarterback Grant Barbera, who accounted for 177 total yards. Barbera completed 12 of 17 passes for 133 yards and also ran for 40 yards on 16 carries with one touchdown. Benjamin Guidry led EDW with 52 rushing yards on four carries. It was the first Prep Classic appearance for Thibodaux-based E.D. White since 1981, the inaugural year of the Prep Classic. The Cardinals were the runner-up to John Curtis that year were the Division II select runners-up to University High in 2021 final played at UL’s Cajun Field.

LISBON, Portugal (AP) — The goals are flying in again for Arsenal — and it just happens to coincide with the return from injury of Martin Odegaard. Make that eight goals in two games since the international break for Arsenal after its 5-1 hammering of Sporting Lisbon in the Champions League on Tuesday, tying the English team’s heaviest ever away win in the competition. Odegaard is back in Arsenal’s team after missing two months with an ankle injury . In that time, Mikel Arteta’s attack stuttered, with a 2-0 loss to Bournemouth and a 1-0 defeat at Newcastle dropping the Gunners well off the pace in the Premier League. There was also a 0-0 draw at Atalanta in the Champions League as well as a 1-0 loss to Inter Milan last month, when Odegaard made his comeback from injury as an 89th-minute substitute. Since then, Arsenal hasn’t lost and the goals have returned. After a 3-0 win over Nottingham Forest on Saturday came the cruise in Lisbon — and Odegaard was at the heart of everything as Sporting’s unbeaten start to the season came to an end. “He’s an unbelievable player,” Arsenal winger Bukayo Saka said of Odegaard. “The day he returned, there was a big smile on my face. You can see the chemistry we have. I hope he stays fit for the rest of the season.” Odegaard was involved in the build-up to Arsenal’s first two goals against Sporting — scored by Gabriel Martinelli and Kai Havertz — and was fouled to win the penalty converted by Saka in the 65th to restore Arsenal’s three-goal lead at 4-1. Odegaard was seen flexing his leg after that but continued untroubled and was substituted in the 78th minute. The last thing Arteta would want now is another injury to Odegaard as Arsenal attempts to reel in first-place Liverpool in the Premier League. Liverpool is already nine points ahead of fourth-place Arsenal after 12 games. ___ AP soccer: https://apnews.com/hub/soccer The Associated PressActivating Your Credit Card? Don’t Skip the Mobile Wallet Step( MENAFN - 3BL) By Candace Higginbotham Ever heard of the benefits cliff? It's a term to describe the impact of a sudden or gradual decrease in public benefits that occurs when a family's income exceeds the eligibility threshold for an assistance program. People who participate in programs like Supplemental Nutrition Assistance Program (SNAP) and Children's health Insurance Program (CHIP) or receive childcare subsidies or child tax credits can face a benefits cliff when they get a raise, take a new job or simply work more hours. This seemingly positive wage increase can result in an individual making too much money to receive the benefits – but not enough to sustain themselves and their household. In short, their income gain results in them being worse off financially than before the income gain (a benefits cliff), or no better off (a benefits plateau). And that can have significant consequences for families and communities: it can keep people in low-wage jobs, discourage them from joining the workforce and influence other decisions that hold them back from long-term financial success. Education and workforce readiness is one of Regions Bank's community engagement priority areas and the bank offers wide-ranging support to community partners that provide job readiness programs, skills training and career coaching. These organizations are well aware of the benefits cliff problem – and the lack of simple solutions. So, as part of its Important Insights series, the Regions Making Life Better Institute® recently hosted a webinar to provide tools and information to help community partners prepare their clients for some of the difficult realities of career advancement. Regions invited Alex Ruder, Community and Economic Development director and principal adviser at the Federal Reserve Bank of Atlanta, to expand understanding of the benefits cliff. Ruder began the discussion with a case study that demonstrates the benefits cliff and plateau, by walking participants through a familiar example: A person working full-time in a near-minimum wage job participating in public assistance programs wants to enter the health care sector to increase their career and financial opportunities. He outlined points in the person's career trajectory where their net financial resources would actually decline or remain the same, even with pay raises, additional certifications and promotions. According to Ruder, there are three potential ways for nonprofits to assist clients who may face a benefits cliff in their journey from entry level to a living wage job. “Building skills, getting certifications and pursuing new roles are proven ways people can advance their career and increase economic mobility,” said Leroy Abrahams, head of Community Engagement at Regions.“Engaging in dialogue with our community partners and workforce development experts helps foster prosperity in our communities.” The webinar participants, representing community organizations around the country, welcomed the discussion and resources. “This has been a terrific presentation and really makes me think of new ways to have conversations that are simple and purposeful that contacts can understand and feel confident regarding their future,” said Dr. Douglas Stewart of the Tennessee College of Applied Technology. That's the reaction that Gina Sian, head of the Regions Making Life Better Institute, was hoping for. “Regions launched this program of free webinars four years ago to help our valuable community partners navigate challenges and provide technical assistance as they work toward their mission,” Sian said.“Investing in knowledge-sharing and skill-building opportunities like these deepen our understanding of the barriers that our communities face and helps us work collaboratively together toward meaningful solutions.” MENAFN13122024007202015466ID1108992037 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

TikTok Owner Pleads For Legal Relief Against US TikTok BanUltra-High Performance Concrete Market to Reach $1,048.2 million, Globally, by 2032 at 5.3% CAGRKörber PharmaThe criminal case in federal court in Massachusetts charges the men, identified as Mahdi Mohammad Sadeghi and Mohammad Abedininajafabadi, with export control violations. U.S. officials blamed the January attack on the Islamic Resistance in Iraq, an umbrella group of Iran-backed militias that includes Kataib Hezbollah. Three Georgia soldiers — Sgt. William Jerome Rivers of Carrollton, Sgt. Breonna Moffett of Savannah and Sgt. Kennedy Sanders of Waycross — were killed in the Jan. 28 drone attack on a U.S. outpost in northeastern Jordan called Tower 22. In the attack, the one-way attack drone may have been mistaken for a U.S. drone that was expected to return back to the logistics base about the same time and was not shot down. Instead, it crashed into living quarters, killing the three soldiers and injuring more than 40. Tower 22 held about 350 U.S. military personnel at the time. It is strategically located between Jordan and Syria, only 10 kilometers (6 miles) from the Iraqi border, and in the months just after Hamas’ Oct. 7 attack on Israel, and Israel’s blistering response in Gaza, Iranian-backed militias intensified their attacks on U.S. military locations in the region. Following the attack, the U.S. launched a huge counterstrike against 85 sites in Iraq and Syria used by Iran's Revolutionary Guard and Iranian-backed militia and bolstered Tower 22’s defenses. Tucker and Copp reported from Washington.

All the hard work the Vikings put in on Sunday afternoon at Soldier Field almost fell by the wayside after they failed to recover an onside kick in the final minute. That paved the way for Chicago Bears kicker Cairo Santos to send the game into overtime with a 48-yard field goal as time expired. ADVERTISEMENT As proud as head coach Kevin O’Connell was that the Vikings still managed to escape with a 30-27 overtime win, he also was irked that lack of execution on the onside kick nearly cost them. What went wrong? Though it looked like nothing more than a fluky bounce, it was actually a misread by tight end Johnny Mundt that resulted in the ball hitting him. Asked about the particular play, special teams coordinator Matt Daniels said as soon as Mundt realized it was going to be a watermelon kick, he should’ve attacked the ball rather than engaged in a block. “He’s got to have some awareness right there,” Daniels said. “He didn’t see where the ball was at.” The use of the watermelon kick has become much more common across the NFL over the past few seasons. It’s executed by placing the ball on its side and kicking the point to create a spinning motion. The hope is to create enough spin with the watermelon kick that the ball travels the required 10 yards. The only issue? The rules say the kicking team can’t touch any member of the receiving team on an onside kick until the ball crosses 10 yards. ADVERTISEMENT That’s why Daniels has stressed to his players the importance of attacking the ball in those situations. “That’s the No. 1 thing,” Daniels said. “As soon as we see it’s a watermelon kick, we are going to go get the ball.” Pace on injured list After suffering a hamstring injury over the weekend, linebacker Ivan Pace Jr. has been placed on injured reserve. As a result, he will have to miss at least the next month, with the Vikings hoping he can be ready to return by the time the playoffs roll around. It’s a tough blow for the Vikings heading into the home stretch as Pace has developed into a key contributor on defense. As a way to add some depth amid the loss, the Vikings signed linebacker Jamin Davis to their active roster, poaching him from the Green Bay Packers, who had signed him to their practice squad. There might be some untapped potential in Davis considering the Washington Commanders selected him in the first round of the 2021 draft. He has totaled 282 tackles, seven sacks, an interception and a pair of forced fumbles across 50 NFL games. Additionally, the Vikings also activated edge rusher Gabe Murphy from injured reserve. ADVERTISEMENT Quessenberry fills in The benefit of having veteran left tackle David Quessenberry on the roster is that he has proven capable of going into a game on short notice. After stepping up last month when star left tackle Christian Darrisaw went down with a knee injury, Quessenberry had his number called over the weekend when veteran left tackle Cam Robinson left the game with a foot injury. Though there were some ups and downs for Quessenberry in the game, his presence allowed the Vikings to continue to run their offense. “I thought he came in and played really well,” offensive coordinator Wes Phillips said. “The left side really wasn’t an issue with him in there. We weren’t thinking like, ‘Oh god. We’ve got to get chips over there. We’ve got to try to formation these things where we can help him out every play.’ We felt pretty comfortable with him felling in and playing that role.” Evans gets claimed After being cut by the Vikings over the weekend, cornerback Akayleb Evans was claimed off waivers by the Carolina Panthers. It will be a fresh start for Evans as he looks to get his career back on track. Though he started 15 games for the Vikings last season, Evans barely played at all on defense this season. He was buried on the depth chart behind veteran cornerbacks Stephon Gilmore, Byron Murphy Jr., and Shaq Griffin. Why didn’t it work out for Evans? ADVERTISEMENT “Sometimes it becomes a numbers situation,” defensive coordinator Brian Flores said. “He’s a talented player who has a place in this league. I wish him all the best in Carolina. He’s going to do a great job for them.” ______________________________________________________ This story was written by one of our partner news agencies. Forum Communications Company uses content from agencies such as Reuters, Kaiser Health News, Tribune News Service and others to provide a wider range of news to our readers. Learn more about the news services FCC uses here .LAS VEGAS , Dec. 16, 2024 /PRNewswire/ -- CTLA-4 inhibitors are a well-established market in cancer care, and they are expected to grow significantly in the coming years. This is due to the expected label expansion and usage of the blockbuster YERVOY and an increasing number of new clinical studies evaluating better-acting versions of CTLA-4 inhibitors in various types of cancers. Other market drivers include increased usage of CTLA-4 inhibitors in combination with other immune checkpoint inhibitors and the increasing prevalence of cancer cases. DelveInsight's CTLA-4 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging CTLA-4 inhibitors, market share of individual therapies, and current and forecasted CTLA-4 inhibitors market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ), the United Kingdom , and Japan ]. Key Takeaways from the CTLA-4 Inhibitors Market Report As per DelveInsight's analysis, the total market size of CTLA-4 inhibitors in the 7MM is expected to surge significantly by 2034. In 2023, YERVOY registered global sales of more than USD 2 billion , followed by IMJUDO which closed 2023 with more than USD 200 million in global sales. YERVOY in combination with OPDIVO is approved for multiple indications in first-line settings including metastatic Melanoma, mesothelioma, Renal Cell Carcinoma, NSCLC, Esophageal cancer, Gastric Cancer, and other second-line indications. There are other newer indications where the combo is being evaluated. Established CTLA-4 inhibitor companies include Bristol Myers Squibb (BMS) and AstraZeneca, Leading emerging CTLA-4 inhibitor companies such as Merck , Xilio therapeutics, BioNTech, Agenus, Bioatla OncoC4, and others are developing novel CTLA-4 inhibitors that can be available in the CTLA-4 inhibitors market in the coming years. Some of the key CTLA-4 inhibitors in the pipeline include Quavonlimab (MK-1308), gotistobart ( ONC-392/BN316 ), BA3071 , and others. Discover which therapies are expected to grab the CTLA-4 inhibitors market share @ CTLA-4 Inhibitors Market Report CTLA-4 Inhibitors Market Dynamics In recent years, the CTLA-4 inhibitors market has been shaped by significant advances in cancer immunotherapy. The growing use of combination therapies , particularly the pairing of CTLA-4 inhibitors with PD-1/PD-L1 inhibitors (like nivolumab or pembrolizumab), has transformed the treatment landscape for several cancers, including melanoma, renal cell carcinoma, and non-small cell lung cancer (NSCLC). This combination approach has demonstrated improved survival benefits , broadening the market for CTLA-4 inhibitors beyond their original monotherapy applications. Additionally, research is ongoing to explore the use of these drugs in other cancers such as colorectal and pancreatic cancer, further fueling market growth. However, market dynamics are influenced by several factors, including the high cost of immunotherapy treatments and the side effects associated with CTLA-4 inhibitors . Immune-related adverse events (irAEs) like colitis, hepatitis, and dermatitis are common due to the drug's effect of ramping up immune activity. As a result, healthcare providers are cautious in prescribing these treatments , and pharmaceutical companies are working on optimizing dosing regimens and exploring biomarkers that could predict which patients will respond best to CTLA-4 inhibition. These considerations impact pricing, regulatory approval, and overall market uptake. The competitive landscape is also heating up as more pharmaceutical companies enter the immunotherapy space. While Bristol- Myers Squibb's ipilimumab has dominated the market, new players and biosimilars are emerging. Additionally, research into next-generation CTLA-4 inhibitors and alternative immune checkpoint targets (like LAG-3 and TIGIT) could change the market dynamics further. The evolution and improvisation of this class can be seen through the development of Fc-enhanced tumor-activated anti-CTLA-4 inhibitors (Xilio's Therapeutics' Vilastobart) which also deplete regulatory T cells when activated (unmasked) in the tumor microenvironment (TME). The innovations in drug delivery and therapeutic combinations , is likely to drive new developments in this area, attracting substantial investment and strategic partnerships. Overall, the CTLA-4 inhibitors market remains highly promising, buoyed by the increasing global burden of cancer , the expanding role of immunotherapy in oncology, and the significant unmet need in the treatment of several aggressive cancers. Advances in research and clinical trials , along with ongoing regulatory approvals, are expected to keep this market growing in the foreseeable future. However, balancing efficacy, safety, and cost will be critical for both pharmaceutical companies and healthcare providers to ensure the sustained success of CTLA-4 inhibitors. CTLA-4 Inhibitors Treatment Market Approved CTLA-4 inhibitors at present are YERVOY (ipilimumab) and IMJUDO (tremelimumab-actl). In March 2011 , YERVOY was the first cancer immunotherapy approved for melanoma, specifically targeting CTLA-4. At that time, it was the only approved treatment for unresectable or metastatic melanoma that showed a significant enhancement in overall survival. The FDA's approval of YERVOY represents the result of over 14 years of research and development by BMS teams, as well as clinical trials involving 676 patients with unresectable or metastatic melanoma who had previously received one or more treatments, including aldesleukin, dacarbazine, temozolomide, fotemustine, or carboplatin, in a randomized Phase III clinical trial. IMJUDO is a human monoclonal antibody designed to inhibit the activity of CTLA-4. By blocking CTLA-4, it promotes T-cell activation, which enhances the immune response against cancer and encourages the destruction of cancer cells. With its initial regulatory approval, patients in the US suffering from unresectable liver cancer now have access to an approved dual immunotherapy treatment regimen that uniquely combines CTLA-4 inhibition with a PD-L1 inhibitor, thereby amplifying the immune response to their cancer. YERVOY currently leads the CTLA-4 inhibitor market, generating over USD 2 billion in sales in 2023, while IMJUDO ended the year with sales exceeding USD 200 million . However, numerous CTLA-4 inhibitors are in clinical trials, with some utilizing innovative proprietary technologies in their development, which could pose a significant challenge to YERVOY's market dominance in the future. Learn more about the FDA-approved CTLA-4 inhibitors @ CTLA-4 Inhibitors Drugs Key Emerging CTLA-4 Inhibitors and Companies Several key emerging players, including Merck, BioNTech, Agenus, BioAtla , and others, are involved in developing drugs for CTLA-4 inhibitors for various indications such as metastatic castration-resistant prostate cancer, breast cancer, cervical cancer, non-squamous cell lung cancer, and others. OncoC4/BioNTech's BNT316/ONC-392 (gotistobart) is a next-generation anti-CTLA-4 antibody being co-developed by BioNTech and OncoC4. It is in late-stage clinical trials, either as a monotherapy or in combination with other treatments, targeting various cancers including non-small cell lung cancer, ovarian cancer, high-grade serous adenocarcinoma of the ovary, primary peritoneal carcinoma, and fallopian tube cancer. CTLA-4 is an immune checkpoint receptor that suppresses T cell responses, limiting their ability to identify and destroy cancer cells. Gotistobart is designed to counteract this suppression while maintaining CTLA-4 recycling, which helps preserve T cell immunosuppressive function in peripheral tissues. This approach, now under clinical evaluation, aims to reduce immune-related side effects. BioAtla's BA3071 is a conditionally active biologic (CAB) anti-CTLA-4 antibody being developed as an immuno-oncology agent. It aims to provide efficacy comparable to existing anti-CTLA-4 antibodies, but with reduced toxicity due to its selective activity in the tumor microenvironment. While blocking CTLA-4 has been shown to enhance antitumor responses, it can also cause immune-related damage to healthy cells. To reduce this risk of on-target, off-tumor effects, BioAtla has used its proprietary CAB technology to ensure that BA3071 binds to the CTLA-4 receptor only on T cells within the tumor microenvironment. This design is intended to enhance both the efficacy and safety of anti-CTLA-4 therapy, whether used alone or in combination with other treatments, by activating T cells specifically in the tumor site. BA3071 is currently in Phase II trials for treating various solid tumors that respond to CTLA-4 inhibition in combination with a PD-1 blocking agent. The anticipated launch of these emerging therapies are poised to transform the CTLA-4 inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CTLA-4 inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about CTLA-4 inhibitors clinical trials, visit @ CTLA-4 Inhibitors Treatment Drugs CTLA-4 Inhibitors Overview CTLA-4 inhibitors are a class of immune checkpoint inhibitors that target cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a protein expressed in T cells. CTLA-4 plays a crucial role in downregulating immune responses by binding to B7 molecules on antigen-presenting cells (APCs), which suppresses T-cell activation. By inhibiting CTLA-4, these drugs block the suppression of T cells, thereby enhancing the immune system's ability to recognize and destroy cancer cells. This mechanism has made CTLA-4 inhibitors an essential part of cancer immunotherapy, particularly in treating advanced-stage malignancies like melanoma. Ipilimumab, the first approved CTLA-4 inhibitor, has shown significant survival benefits in clinical trials, leading to its use in combination with other immune checkpoint inhibitors, such as PD-1 inhibitors, to further improve patient outcomes. While CTLA-4 inhibitors have shown promise in cancer therapy, their use comes with challenges, particularly immune-related adverse events (irAEs). These adverse effects occur because the inhibition of CTLA-4 can lead to excessive immune activation, which may result in the immune system attacking normal tissues and organs. Common irAEs include colitis, dermatitis, and hepatitis. Managing these side effects requires a delicate balance between maintaining the anti-cancer immune response and mitigating harmful autoimmune reactions. Despite these challenges, the clinical benefits of CTLA-4 inhibitors have made them a vital component in the fight against cancer, driving ongoing research into their optimization and use in combination therapies. CTLA-4 Inhibitors Report Metrics Details Study Period 2020–2034 CTLA-4 Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key CTLA-4 Inhibitors Companies Bristol Myers Squibb, AstraZeneca, Merck, Xilio therapeutics, BioNTech, Agenus, Bioatla OncoC4, Aadageneand others Key CTLA-4 Inhibitors YERVOY,IMJUDO, Quavonlimab, ONC-392/BN316 (gotistobart), BA3071, and others Scope of the CTLA-4 Inhibitors Market Report CTLA-4 Inhibitors Therapeutic Assessment: CTLA-4 Inhibitors current marketed and emerging therapies CTLA-4 Inhibitors Market Dynamics: Conjoint Analysis of Emerging CTLA-4 Inhibitors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, CTLA-4 Inhibitors Market Access and Reimbursement Discover more about CTLA-4 inhibitors in development @ CTLA-4 Inhibitors Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Key Highlights 4 Executive Summary of CTLA-4 Inhibitor 5 Key Events 6 Target Addressable Pool and Market Forecast Methodology 7 CTLA-4 Inhibitor Market Overview at a Glance in the 7MM 7.1 Market Share (%) Distribution by Therapies in 2023 7.2 Market Share (%) Distribution by Therapies in 2034 8 Background and Overview 8.1 Introduction 8.2 Treatment 9 Target Patient Pool 9.1 Key Findings 9.2 Assumptions and Rationale: 7MM 9.3 Epidemiology Scenario in the 7MM 9.3.1 Total Cases in Selected Indications for CTLA-4 Inhibitor in the 7MM 9.3.2 Total Eligible Patient Pool for CTLA-4 Inhibitor in Selected Indications in the 7MM 9.3.3 Total Treated Cases in Selected Indications for CTLA-4 Inhibitor in the 7MM 10 Marketed Drugs 10.1 Key Competitors 10.2 YERVOY: Bristol Myers and Squibb (BMS) 10.2.1 Product description 10.2.2 Regulatory milestones 10.2.3 Other development activities 10.2.3.1 Clinical development 10.2.4 Safety and efficacy 10.3 IMJUDO: Astrazeneca 10.3.1 Product description 10.3.2 Regulatory milestones 10.3.3 Other development activities 10.3.3.1 Clinical development 10.3.4 Safety and efficacy 11 Emerging Therapies 11.1 Key Competitors 11.2 Quavonlimab: Merck 11.2.1 Product description 11.2.2 Other developmental activities 11.2.3 Clinical development 11.2.4 Safety and efficacy 11.3 Vilastobart: Xilio therapeutics 11.3.1 Product description 11.3.2 Other developmental activities 11.3.3 Clinical development 11.3.4 Safety and efficacy 11.4 BA3071: BioAtla 11.4.1 Product description 11.4.2 Other developmental activities 11.4.3 Clinical development 11.4.4 Safety and efficacy *List to be continued in the report 12 CTLA-4 Inhibitor: 7MM analysis 12.1 Key Findings 12.2 Market Outlook 12.3 Conjoint Analysis 12.4 Key Market Forecast Assumptions 12.4.1 Cost Assumptions and Rebates 12.4.2 Pricing Trends 12.4.3 Analogue Assessment 12.4.4 Launch Year and Therapy Uptakes 12.5 United States Market Size 12.5.1 Market Size by Indications in the US 12.5.2 Market Size by Therapies in the US 12.6 EU4 and the UK Market Size 12.6.1 Market Size by Indications in EU4 and the UK 12.6.2 Market Size by Therapies in EU4 and the UK 12.7 Japan Market Size 12.7.1 Market Size by Indications in Japan 12.7.2 Market Size by Therapies in Japan 13 Unmet Needs 14 SWOT Analysis 15 KOL Views 16 Market Access and Reimbursement 17 Appendix 17.1 Bibliography 17.2 Report Methodology 18 DelveInsight Capabilities 19 Disclaimer 20 About DelveInsight Related Reports Non-small Cell Lung Cancer Market Non-small Cell Lung Cancer Market Insight, Epidemiology and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma , among others. Non-small Cell Lung Cancer Pipeline Non-small Cell Lung Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang , Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical, Pierre Fabre , Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, among others. Ovarian Cancer Market Ovarian Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key ovarian cancer companies including Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co, Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, VBL Therapeutics, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics , among others. Ovarian Cancer Pipeline Ovarian Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ovarian cancer companies, including Gradalis, VBL Therapeutics, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur info@delveinsight.com +14699457679 Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

Donald Trump wasted no time picking a replacement nominee for Attorney General after Matt Gaetz withdrew his name from consideration. "I am proud to announce former Attorney General of the Great State of Florida, Pam Bondi, as our next Attorney General of the United States," Trump announced in a post on Truth Social Thursday evening. Advertisement "For too long, the partisan Department of Justice has been weaponized against me and other Republicans—Not anymore," Trump added. "Pam will refocus the DOJ to its intended purpose of fighting Crime, and Making America Safe Again." And the liberal media wasted no time flipping out after Bondi was announced as the new nominee. Which is exactly how we know this was a great pick from Trump. Case in point: MSNBC political contributor Jason Johnson, a political science professor at Morgan State University, went on an unhinged rant about why Pam Bondi will be "worse" than Matt Gaetz would have been. "Pam Bondi is what we should all fear cuz she's competent. We may not agree with her ideologically, but she actually knows how to do this job," Johnson said. "So, if anyone on the Democratic side or anyone — or anyone who cared about liberty and justice was thinking 'Well maybe Matt Gaetz will screw this up and that will give us some time,' well, no." Recommended: Sen. Bob... Matt MargolisMaine's voter-approved limit on PAC contributions triggers lawsuit in federal court

MIAMI--(BUSINESS WIRE)--Dec 16, 2024-- KEO World (KEO), a fintech leader in B2B digital payments and inventory financing, today announced that it has taken a significant step in its expansion. Through a partnership agreement with BTG Pactual Bank S.A., the largest investment bank in Latin America, KEO World will expand its operations in the Brazilian market. As part of the partnership, KEO's Workeo solution , in collaboration with the Amex Business Link PlatformTM, can help thousands of medium and large businesses in Brazil digitize their B2B invoice payments, which can result significant cost efficiencies and increased purchasing power. Founded in 2020, KEO has experienced rapid growth. KEO's Workeo solution, powered by KEO's flagship credit processing, provides businesses with a working capital line of credit through a digital wallet within a multi-product payment and billing rails, available via Amex Business LinkTM. Additionally, KEO offers its own proprietary blockchain payment rails, known as KEO Rails TM, to help make payments even easier. "We are delighted to have agreed to this partnership agreement with one of the largest financial institutions in South America, which will allow us to increase the reach of our B2B digital payments program and provide financing to many more companies in Brazil," said Paolo Fidanza , Founder and CEO of KEO. "In a market where less than 10% of total traditional credit is extended to SMEs, our Workeo product enables business buyers to access core inventory on credit and suppliers to increase their recurring sales, enhancing working capital management through a fully digital, frictionless, and low-cost financing and cash management platform thanks to our innovative payment rails, credit processing, and the American Express network." "Expanding the value proposition of the Amex Business LinkTM platform is one of our priorities so that buyers and suppliers can make real-time decisions that optimize their working capital and improve their operational-administrative and reconciliation processes. Thanks to this expansion, companies in Brazil will be able to access an innovative and 100% digital ecosystem that offers digital payment and billing tools for local and international transactions," said René Centeno, American Express, Supply Chain Solutions Global Head. About KEO World Founded in 2020, KEO World is a leading innovator of technology-based financial solutions with a mission to provide businesses with digital, seamless and secure ways to finance their supplies and increase efficiency in their cash flow. KEO is headquartered in Miami, Florida, with operations in the US, Canada, Mexico, and throughout Latin America. The company was the first non-bank financial institution to receive an American Express issuing license. To learn more, visit www.KEOworld.com . About American Express American Express is a globally integrated payments company, providing customers access to products, insights and experiences that enrich lives and build business success. Learn more at americanexpress.com and connect with us at facebook.com/americanexpress , instagram.com/americanexpress , linkedin.com/company/american-express , twitter.com/americanexpress and youtube.com/americanexpress . American Express ® is a brand of American Express. Workeo is issued by KEO World S.A. de C.V., SOFOM, E.N.R. under license from American Express. KEO presents Workeo, a credit solution through the Amex Business LinkTM platform. View source version on businesswire.com : https://www.businesswire.com/news/home/20241216985773/en/ CONTACT: KEO World Media Contact Carlos Mejia Public Realtions carlos@elfashonguru.tv KEYWORD: FLORIDA LATIN AMERICA NORTH AMERICA UNITED STATES BRAZIL SOUTH AMERICA INDUSTRY KEYWORD: TECHNOLOGY PAYMENTS FINANCE FINTECH BANKING OTHER TECHNOLOGY PROFESSIONAL SERVICES SOFTWARE SMALL BUSINESS DATA MANAGEMENT SOURCE: KEO World Copyright Business Wire 2024. PUB: 12/16/2024 05:52 PM/DISC: 12/16/2024 05:50 PM http://www.businesswire.com/news/home/20241216985773/en

Ross Barkley’s 85th-minute goal gave them victory in Germany after goals from John McGinn and Jhon Duran early in each half were cancelled out by Lois Openda and Christoph Baumgartner. That sent them up to third in the new league phase of the competition ahead of Wednesday’s games and with matches against Monaco and Celtic to come, Villa have an excellent chance of finishing in the top eight. Job done... in the end 😅 #RBLAVL #UCL pic.twitter.com/PRD1Hi1Q3A — Aston Villa (@AVFCOfficial) December 10, 2024 That would mean they would avoid a play-off round to make it through to the last 16 and Emery says that is the target. “Today was key. Juventus at home, we were thinking more to win but in the end we accepted the draw because it was important for a point to be more or less in the top 24,” he told Amazon Prime. “Today was a match we were thinking at the beginning was key to be a contender to be in the top eight with the last two matches to be played. “It is going to be difficult and we have to get some more points but we now have the possibility to achieve this option. “We are going to enjoy and try to get top eight but we have to be happy because we are in the top 24 and maybe even the top 16. “We weren’t contenders in the beginning to get there but now we have to accept it.” Leipzig, who are flying high near the top of the Bundesliga, are out after losing all six matches. They did pose a threat to Villa, who inflicted some of their own problems on themselves, notably a rare gaffe from goalkeeper Emiliano Martinez for Openda’s equaliser. But Emery was happy with his side’s performance. “I try to enjoy and always we want to improve and sometimes it is hard but today the team were performing well, playing seriously and I was enjoying it,” he added. “We tried to overcome the mistakes we made and we did. More or less we were playing consistently. One mistake and they score but then we played very well. “Champions League is very difficult and we have to expect that every team playing at home are feeling strong. We played with consistency and domination.”Ravens' running game was crucial in a big win over the Chargers, especially on 4th down

Which Jackson-area football players took home all-state honors?

None'Unbelievable' Odegaard transforms Arsenal and gets Saka smiling again

NoneManchester City defender Nathan Ake said his side must “show character” if they are to end their winless streak after Feyenoord scored three times in the final 15 minutes to claim a 3-3 draw in the Champions League at the Etihad Stadium. City are now six games without a victory but appeared to be cruising towards three points before being stunned by the Eredivisie side, who hit them with goals from Anis Hadj Moussa, Santiago Gimenez and David Hancko to fight back from 3-0 down. Two goals from Erling Haaland , one of them a penalty, and one from Ilkay Gundogan had the 2023 European champions three up after 53 minutes as they sought the win that would help to get their ailing season back on track. After the team collapsed in the closing stages, Ake called on his team-mates to show their mettle if their campaign is not to wither away. Speaking to Amazon Prime, he was asked whether he believed the the team’s problem is a mental one. “Maybe it is,” he said. “It is difficult to say. Obviously we have not been in this situation many times but this is where we have to show our character. “When everything seems to go against us and everyone is writing us off, we have to stay strong mentally, believe in ourselves and stick together. “Every season there is a period when they write us off. We have to make sure we stay strong as a team and staff and make sure we get out of it.” The draw leaves City with work to do if they are to secure one of the eight automatic spots in the last 16 of this season’s Champions League. They are currently 15th in the table, two points outside of the top eight, and will need positive results in their next two games against Juventus and Paris St Germain to keep their hopes alive. They then face Club Brugge in their final league match on January 29. The result at least ended a run of five straight defeats in all competitions ahead of Sunday’s Premier League showdown with leaders Liverpool at Anfield. “When you are three goals up it feels like a defeat when you give up three goals at home,” said Ake. “It is tough now, a tough night, but the only thing we can do is look forward to the next one. Liverpool is a big game and it is another challenge to overcome. “(We were) 3-0 up and we played quite well and were under control, but then it all changed. “You just have to stay strong mentally. At 3-1 they then push on but I think we need to go for it a bit earlier so we could keep the pressure on them, but we stayed playing at the back and maybe invited more pressure on us. “Then when you concede the second one there is even more pressure and then we have to stay stronger mentally.”

NEW YORK (AP) — U.S. stock indexes drifted lower Tuesday in the runup to the highlight of the week for the market, the latest update on inflation that’s coming on Wednesday. The S&P 500 dipped 0.3%, a day after pulling back from its latest all-time high . They’re the first back-to-back losses for the index in nearly a month, as momentum slows following a big rally that has it on track for one of its best years of the millennium . The Dow Jones Industrial Average fell 154 points, or 0.3%, and the Nasdaq composite slipped 0.3%. Tech titan Oracle dragged on the market and sank 6.7% after reporting growth for the latest quarter that fell just short of analysts’ expectations. It was one of the heaviest weights on the S&P 500, even though CEO Safra Catz said the company saw record demand related to artificial-intelligence technology for its cloud infrastructure business, which trains generative AI models. AI has been a big source of growth that’s helped many companies’ stock prices skyrocket. Oracle’s stock had already leaped more than 80% for the year coming into Tuesday, which raised the bar of expectations for its profit report. In the bond market, Treasury yields ticked higher ahead of Wednesday’s report on the inflation that U.S. consumers are feeling. Economists expect it to show similar increases as the month before. Wednesday’s update and a report on Thursday about inflation at the wholesale level will be the final big pieces of data the Federal Reserve will get before its meeting next week, where many investors expect the year’s third cut to interest rates . The Fed has been easing its main interest rate from a two-decade high since September to take pressure off the slowing jobs market, after bringing inflation nearly down to its 2% target. Lower rates would help give support to the economy, but they could also provide more fuel for inflation. Expectations for a series of cuts through next year have been a big reason the S&P 500 has set so many records this year. Trading in the options market suggests traders aren’t expecting a very big move for U.S. stocks following Wednesday’s report, according to strategists at Barclays. But a reading far off expectations in either direction could quickly change that. The yield on the 10-year Treasury rose to 4.22% from 4.20% late Monday. Even though the Fed has been cutting its main interest rate, mortgage rates have been more stubborn to stay high and have been volatile since the autumn. That has hampered the housing industry, and homebuilder Toll Brothers’ stock fell 6.9% even though it delivered profit and revenue for the latest quarter that topped analysts’ expectations. CEO Douglas Yearley Jr. said the luxury builder has been seeing strong demand since the start of its fiscal year six weeks ago, an encouraging signal as it approaches the beginning of the spring selling season in mid-January. Elsewhere on Wall Street, Alaska Air Group soared 13.2% after raising its forecast for profit in the current quarter. The airline said demand for flying around the holidays has been stronger than expected. It also approved a plan to buy back up to $1 billion of its stock, along with new service from Seattle to Tokyo and Seoul . Boeing climbed 4.5% after saying it’s resuming production of its bestselling plane , the 737 Max, for the first time since 33,000 workers began a seven-week strike that ended in early November. Vail Resorts rose 2.5% after the ski resort operator reported a smaller first-quarter loss than analysts expected in what is traditionally its worst quarter. All told, the S&P 500 fell 17.94 points to 6,034.91. The Dow dipped 154.10 to 44,247.83, and the Nasdaq composite slipped 49.45 to 19,687.24. In stock markets abroad, indexes were mixed in China after the world’s second-largest economy said its exports rose by less than expected in November. Stocks rose 0.6% in Shanghai but fell 0.5% in Hong Kong. Indexes fell across much of Europe ahead of a meeting this week by the European Central Bank, where the widespread expectation is for another cut in interest rates. AP Business Writers Matt Ott and Elaine Kurtenbach contributed. Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. Get local news delivered to your inbox!Shipping poised to play a vital role in APAC cross-border CCUS initiatives, with annual CO2 shipping volumes projected to reach 100 MtPA by 2050